



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete if Known	
				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-20040018180-A1	01-29-2004	Boyd		
AB*	US-20040132179	07-08-2004	Boyd		
AC*	US-20040241842-A1	12-02-2004	Boyd		
AD*	US-20040258672-A1	12-23-2004	Boyd		
AE*	US-20040259803	12-23-2004	Boyd		
AF*	US-20040265285	12-30-2004	Boyd		
AG*	US-20040013641-A1	01-22-2004	Boyd		
AH*	US-20050020524	01-27-2005	Boyd		
AI*	US-20050042679	02-24-2005	Boyd et al.		
AJ*	US-20050043245	02-24-2005	Siler-Khodr		
AK*	US-3,972,859	08-03-1976	Fujino et al.		
AL*	US-3,992,365	11-16-1976	Beddell et al.		
AM*	US-4,003,884	01-18-1977	Konig et al.		
AN*	US-4,005,063	01-25-1977	Gendrich et al.		
AO*	US-4,008,209	02-15-1977	Fujino et al.		
AP*	US-4,010,125	03-01-1977	Schally et al.		
AQ*	US-4,010,149	03-01-1977	Baba et al.		
AR*	US-4,018,726	04-19-1977	Schally et al.		
AS*	US-4,024,121	05-17-1977	Schally et al.		
AT*	US-4,089,946	05-16-1978	Foell et al.		
AU*	US-4,100,274	07-11-1978	Dutta et al.		
AV*	US-4,118,483	10-03-1978	Konig et al.		
AW*	US-4,128,638	12-05-1978	Moody		
AX*	US-4,218,439	08-19-1980	Rivier et al.		
AY*	US-4,234,571	11-18-1980	Nestor et al.		
AZ*	US-4,275,001	06-23-1981	Konig et al.		
AA1*	US-4,490,291	12-25-1984	Fujino		
AB1*	US-4,608,251	08-26-1986	Mia		
AC1*	US-4,642,332	02-10-1987	Folkers et al.		
AD1*	US-4,656,247	04-07-1987	Folkers et al.		
AE1*	US-4,775,361	10-04-1988	Jacques et al.		
AF1*	US-4,866,160	09-12-1989	Coy et al.		
AG1*	US-4,992,421	02-12-1991	De et al.		
AH1*	US-5,003,011	03-26-1991	Coy et al.		
AI1*	US-5,061,620	10-29-1991	Tsukamoto et al.		
AJ1*	US-5,073,624	12-17-1991	Coy et al.		
AK1*	US-5,144,019	09-01-1992	Rossi et al.		
AL1*	US-5,199,942	04-06-1993	Gillis		
AM1*	US-5,258,492	11-02-1993	Schally et al.		
AN1*	US-5,399,493	03-21-1995	Emerson et al.		
AO1*	US-5,434,136	07-18-1995	Mathias		
AP1*	US-5,410,016	04-25-1995	Hubbell et al.		
AQ1*	US-5,506,207	04-09-1996	Rivier et al.		
AR1*	US-5,559,703	09-24-1996	Iwata et al.		
AS1*	US-5,614,187	03-25-1997	Sachs		

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				<i>Complete if Known</i>
				Application Number
				10/553594
				Filing Date
				October 18, 2005
				First Named Inventor
				Richard L. BOYD
				Art Unit
				Not Yet Assigned
				Examiner Name
				Not Yet Assigned
Sheet	2	of	10	Attorney Docket Number
				0286336.00159US2/NOR-020US

AT1*	US-5,614,502	03-25-1997	Flotte et al.	
AU1*	US-5,624,823	04-29-1997	Sachs et al.	
AV1*	US-5,643,252	07-01-1997	Waner et al.	
AW1*	US-5,658,564	08-19-1997	Sykes et al.	
AX1*	US-5,658,822	08-19-1997	Wu et al.	
AY1*	US-5,658,892	08-19-1997	Flotte et al.	
AZ1*	US-5,681,559	10-28-1997	DiGiusto et al.	
AA2*	US-5,736,524	04-07-1998	Content et al.	
AB2*	US-5,741,706	04-21-1998	Leavitt et al.	
AC2*	US-5,760,000	06-02-1998	Habibi	
AD2*	US-5,811,275	09-22-1998	Wong-Staal et al.	
AE2*	US-5,814,617	09-29-1998	Hoffman et al.	
AF2*	US-5,839,446	11-24-1998	Waner et al.	
AG2*	US-5,876,708	03-02-1999	Sachs	
AH2*	US-5,985,892	11-16-1999	Walsh et al.	
AI2*	US-6,030,833	02-29-2000	Seebach et al.	
AJ2*	US-6,056,738	05-02-2000	Marchitto et al.	
AK2*	US-6,103,694	08-15-2000	Mardiney et al.	
AL2*	US-6,251,099	06-26-2001	Kollias et al.	
AM2*	US-6,296,846	10-02-2001	Sachs et al.	
AN2*	US-6,306,651	10-23-2001	Sachs	
AO2*	US-6,315,772	11-13-2001	Marchitto et al.	
AP2*	US-6,492,145	12-10-2002	Lowrie	
AQ2*	US-6,558,663	05-06-2003	Seebach et al.	
AR2*	US-6,248,329	06-19-2001	Chandrashekhar et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BA	AU-56394/94		09-01-1994	ORTHO PHARMACEUTICAL CORPORATION	
BB	AU-76177/91		11-19-1992	COMMONWEALTH SERUM LABORATORIES LIMITED	
BC	EP-413209		02-20-1991	ABBOTT LABORATORIES	
BD	EP-364819		04-25-1990	THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND	
BE	EP-217659		04-25-1990	EASTERN VIRGINIA MEDICAL AUTHORITY	
BF	EP-181236		05-14-1986	PITMAN-MOORE, INC	
BG	FR-7923545		09-21-1979		
BH	DK-2509783		09-11-1975	TAKEDA CHEMICAL INDUSTRIES, LTD. OSAKA, JP	
BI	GB-9112859		07-31-1991	IMPERIAL CHEMICAL INDUSTRIES PLC	

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

	BJ	GB-9112825	07-31-1991	IMPERIAL CHEMICAL INDUSTRIES PLC		
	BK	WO-02/31110	04-18-2002	BOYD		
	BL	WO-01/74377	10-11-2001	SILER-KHODR, KHODR		
	BM	WO-01/34815	05-17-2001	CAMBRIA BIOSCIENCES, LLC		
	BN	WO-00/62657	10-26-2000	MONASH UNIVERSITY		
	BO	WO-99/53050	10-21-1999	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION		
	BP	WO-99/32619	07-01-1999	THE CARNEGIE INSTITUTE OF WASHINGTON ET AL		
	BQ	WO-99/29728	06-17-1999	UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE		
	BR	WO-98/23325	06-04-1998	THE GENERAL HOSPITAL CORPORATION		
	BS	WO-98/08533	03-05-1998	PEPTECH LIMITED		
	BT	WO-96/33282	10-24-1996	CHIRON VIAGENE, INC.		
	BU	WO-96/33281	10-24-1996	CHIRON VIAGENE, INC., SYSTEMIX		
	BV	WO-96/22786	08-01-1996	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	BW	WO-96/14853	03-23-1996	UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER		
	BX	WO-92/19746	11-12-1992	CSL LIMITED, COX, John, Cooper, EDWARDS, Stirling, John		
	BY	WO-95/08105	03-23-1995	SYSTEMIX, INC.		
	BZ	WO-94/26877	11-24-1994	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		
	BA1	WO-94/26285	11-24-1994	THE GENERAL HOSPITAL CORPORATION		
	BB1	WO-93/15722	08-19-1993	SYNTEX (USA) INC.		
	BC1	WO-88/01176	02-25-1988	BUNGE (AUSTRALIA) PTY. LTD., BRANDON, Malcolm, Roy		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA	Abdoudkhil, et al., (1991) Scand. J. Immunol. 34, 647-653		
CB	Akashi et al., (1997) Cell 89(7) 1033-1041		
CC	Ali et al., (2000) Transplantation 69:221		
CD	Alpdogan et al., (2001) Blood 98:2256		
CE	Amado et al., (1999) Front. Biosci. 4:D468-475		
CF	Andersen, (1994) Infect. Immunity, 62:2536		
CG	Andrew et al., (2001) J. Immunol. 166(3): 1524-1530		
CH	Andrew et al., (2002) Exp. Gerontol. 37:455		
CI	Aspinall, et al., (2000) Vaccine 18:1629		
CJ	Aspinall, (1997) J. Immunol. 158:3037		
CK	Atassi et al., (2001) Crit. Rev. Immunol. 21:1		
CL	Atlan-Gepner et al., (1999) Autoimmunity 3:249-260		
CM	Bach (1983) Birth Defects Original Article Ser. 19(3): 245-253		
CN	Bahnsen et al., (1997) "Method for Retrovirus-Mediated Gene Transfer to CD34+-Enriched Cells," in Gene Therapy Protocols (P.D. Robbins, ed.), Humana Press, pp.249-263		
CO	Banerjee et al., (1994) Stem Cells 12:378		
CP	Batard et al., (2000) J. Cell. Sci. 113:383-90		
CQ	Basch, (1990) Aging: Immunology and Infectious Disease, Vol. 2, No. 4, 229-235		
CR	Bauer et al., (1997) Blood 89:2259-2267		
CS	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.		
CT	Belmont et al., (1997) "Methods for Efficient Retrovirus-Mediated Gene Transfer to Mouse Hematopoietic Stem Cells," in Gene Therapy Protocols (P.D. Robbins, ed.), Humana Press, pp. 223-240		
CU	Berzins et al., (1999) Proc. Natl. Acad. Sci. USA (17): 9787-9791		
CV	Berzins et al., (1998) J. Exp. Med. 187: 1839		
CW	Bloom et al., (1993) Science 257, 1055		
CX	Bodey et al., (1997) In Vivo 11(4): 351-370		
CY	Bodey et al., (1997) In Vivo 11(5): 421-440		
CZ	Boilotin et al., (1999) Bone Marrow Transplant, 23(8): 783-788		
CA1	Boilotin et al., (1996) Blood 88:1887		
CB1	Bonato et al., (1998) Infection and Immunity, 66(1): 169-175		
CC1	Bonyhadi et al., (1997) J. Virology 71:4707-4716		
CD1	Borremans et al., (1989) Infect. Immunity 57:3123		
CE1	Boyd et al., (1993) Immunology Today 14:445		
CF1	Bruijntjes et al., (1993) Dev. Immunol. 3:113		
CG1	Capecchi, (1980) Cell 22:479-488		
CH1	Carayon et al., (1992) J. Imm. Methods 147:225		
CI1	Castle, (2000) Clin Infect Dis 31(2): 578-585		
CJ1	Charoenvit et al., (1991) J. Immunol. 146: 1020		
CK1	Coleman et al., (1989) Ultrasound Med. Biol. 15:213-227		
CL1	Consolini et al., (2000) Clin. Exp. Immunol. 121(3): 444-447		
CM1	Davis et al. (1998) Hum. Gene Ther., p. 1197-207		
CN1	Dawe et al., (1993) Springer Semin. Immunopathol. 14:285		
CO1	Denis et al., (1998) Infection and Immunity, (66)4:1527-1533		
Examiner Signature		Date Considered	



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

CP1	DeWit et al., (1994) DNA Seq. 4:267
CQ1	DiGusto et al., (1997) Blood 87:1261
CR1	Doria et al.,(1997) Mech. Age. Dev. 95: 131-142
CS1	Douek et al., (2001) J. Immunol. 167:6663-8
CT1	Douek et al., (2000) Lancet 355:1875
CU1	Douek et al., (1998) Nature 396:690
CV1	Dougherty et al., (1995) Curr. Opin. Cell Biol. 7:399
CW1	Doukas et al., (1995) Ultrasound Med. Biol. 21:961
CX1	Dreger et al., (1993) Blood 81:1404
CY1	Ellis, "New Technologies for Making Vaccines," Chapter 29 of "Vaccines", Plotkin et al., 1998, pp. 568-574.
CZ1	Ellis et al., (2001) Int. Immunol. 13:553-558
CA2	Engel et al., (1999) Frontiers in Bioscience 4, e26-33
CB2	Erben et al., (2001) Horm. Metab. Res. (2001) 33:491
CC2	Ernst et al., (1990) J. Immunol. 145:1295
CD2	Ezzell NIH Research, "Cancer 'Vaccines': An Idea Whose Time Has Come?" 1995, Vol. 7, pp. 46-49.
CE2	Fabris et al., (1997) Cell Mol. Biol., 43(4): 529-541
CF2	Fabro et al., (1990) J. Appl. Phys. 68:775,
CG2	Fabris et al., (1995) Aging Apr; 7(2): 77-93
CH2	Faith et al., (1991) Immunol. 74:1
CI2	Faltynek et al., (1992) J. Immunol. 149:1276
CJ2	Fan et al., (2002) J. Immunol. 168:755-62
CK2	Fearon et al., (1996) Science 272:50
CL2	Feldman et al., "Anti-TNF- α Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceeding, 1998, Vol. 30, pp. 4126-4127.
CM2	Fernando et al., (1999) Clin. Exp. Immunol. 115:397
CN2	Fitzpatrick et al., "Reappearance of Thymus of Ageing Rats after Orchidectomy," Journal of Endocrinology, 1985, pp. R17-R19, Vol. 106
CO2	Fitzpatrick et al., (1987) J. Endocr. 113, 51-55
CP2	Flurkey et al., (1992) J. Gerontol. 47:B115
CQ2	Flynn et al., (1992) Proc. Natl. Acad. Sci. USA 89:12013
CR2	Franke et al., (2000) Infect. Immun. 68:3403
CS2	Fredrickson et al., (1994) Development and Comparative Immunology 18:251
CT2	Fry, et al., (2001) Trends Immunol. 22(10): 564-571
CU2	Fry et al., (2001) Blood 97(6): 1525-1533
CV2	Garrovillo et al., (2001) Am. J. Transplant. 1:129
CW2	Garrovillo et al., (1999) Transplantation 68:1827
CX2	Garzetti et al., (1996) Obstet. Gynecol. 88: 234-40
CY2	George et al., (1996) Immunol. Today 17:267
CZ2	Ghalie et al., "Prevention of Hypermenorrhea With Leuprolide in Premenopausal Women Undergoing Bone Marrow Transplantation," American Journal of Hematology, 1993, Vol. 42, pp 350-353.
CA3	Gill et al., (2002) Nat. Immunol. 3:635
CB3	Girasole et al., (1992) J. Clin. Invest. 89:883
CC3	Godfrey et al., (1993) Immunol. Today 14:547
CD3	Godfrey et al., (1990) Immunol. 70:66
CE3	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

Application Number	10/553594
Filing Date	October 18, 2005
First Named Inventor	Richard L. BOYD
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

Sheet 6 of 10 Attorney Docket Number 0286336.00159US2/NOR-020US

CF3	Goldberg et al., (2003) Poster Presentation, ASBMT, Keystone USA
CG3	Goldberg et al., (2003) Abstract, ASBMT, Keystone USA
CH3	Goldberg et al., (2002) Abstract/Poster Presentation ASH, Philadelphia USA
CI3	Goldberg et al., (2002) Abstract of Oral Presentation, Immunology Group of Victoria, Beachworth AU
CJ3	Graham et al., (1973) Virology 52:456-457
CK3	Greenstein et al., (1987) J. Endocr., 112, 345-350
CL3	Greenstein et al., (1986) J. Endocr. 110, 417-422
CM3	Grossman, (1985) Science 227: 256-261
CN3	Grossman, (1984) Endocrine Reviews, 5(3): 435-455
CO3	Hadden, (1998) New York Academy of Sciences, 840: 352-358
CP3	Hannet et al., (1992) Immunol. Today, June; 13(6): 215-218
CQ3	Haseloff et al., (1988) Nature 334:585
CR3	Haynes et al., (1999) J. Clin. Invest. 103: 453-460
CS3	Hazenberg et al., (2001) J. Mol. Med. 79:631-40
CT3	Heitger et al., (2002) Blood 99:4053-4062
CU3	Heitger et al., (1997) Blood 90: 850-857
CV3	Hertogh-Huijbregts et al., (1990) Mech. Ageing Dev. 53:141-155
CW3	Hirokawa, (1998) "Immunity and Ageing," in PRINCIPLES AND PRACTICE OF GERIATRIC MEDICINE, (M. Pathy, ed.) John Wiley and Sons Ltd.
CX3	Hirokawa et al., (1994) Immunology Letters 40:269
CY3	Hirokawa et al., (1975) J. Immunol. 114:1659
CZ3	Hobbs et al., (1993) J. Immunol. 150:3602
CA4	Hochberg et al., (2001) Blood 98:1116-21
CB4	Hoffman et al., (1991) Science 252: 520
CC4	Homo-Delarche et al., (1993) Springer Sem. Immunopathol. 14:221
CD4	Hsu et al., (2000) Cancer Res. 60:3701
CE4	Hu et al., (1993) Int. Immunol. 5:1035-1039
CF4	Huiskamp et al., (1985) J. Immunol., 134(4): 2161-2171
CG4	Huiskamp et al., (1983) Radiation Research 95:370
CH4	Huygen et al., (1992) Infect. Immunity 60:2880
CI4	Igarashi et al., (2001) Proc. Natl. Acad. Sci. USA, 98(26): 15131-15136
CJ4	Jacobson et al. (1999) Endocrinology, 140(8): 3429-3437
CK4	Jacobson et al., (1999) J. Allergy Clin. Immunol., 104(3): Pt. 1, 653-658
CL4	Jacobson et al., (1994) Endocrinology, Vol. 134(6): 2516-2523
CM4	Janeway et al., (2001) Immunobiology 5th Ed., p. 325
CN4	Jansson et al., (1994) J. Neuroimmunology 53:203-207
CO4	Jenkinson et al., (1985) Transplantat. 39:331
CP4	Junker et al., (1998) Hum Gene Ther. , p. 333-40
CQ4	Kamradt et al., (2001) N. Engl. J. Med. 344:655-664.
CR4	Kendall et al., (1990) Cell Tissue Research, 261(3):555-64
CS4	Kendall, (1988) "Anatomical and physiological factors influencing the thymic microenvironment," in THYMUS UPDATE I, Vol. 1. (M. D. Kendall, and M. A. Ritter, eds.) Harwood Academic Publishers, p. 27
CT4	Kincade et al., (2002) Immunology, 14: 385-394
CU4	Kincade et al. (2000) Immunological Reviews, 175: 128-137
CV4	Kirschmann et al., (1992) Cell. Immunol. 139:426
CW4	Kissin et al., (1987) Radiology, 163(1): 67-70
CX4	Kohn et al., (1999) Blood 94:368-371

Examiner Signature	Date Considered
--------------------	-----------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				<i>Complete if Known</i>	
Sheet	7	of	10	Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	0286336.00159US2/NOR-020US

CY4	Kohen et al., (1998) Developmental Immunology, 5: 277-285
CZ4	Kojima et al., "Immunosuppressive Therapy Using Antithymocyte Globulin, Cyclosporine, and Danazol With or Without Human Granulocyte Colony-Stimulating Factor in Children With Acquired Aplastic Anemia." Blood, September 15, 2000, Vol. 96, No. 6, pp 2049-2054
CA5	Komschlies et al., (1995) J. Leukoc. Biol. Dec.; 58(6): 623-633
CB5	Kourou et al., (2001) Blood 97:2708
CC5	Krijanovski, et al., (1999) Blood 94:825
CD5	Krug (2004) Sem. Oncol. 31:112
CE5	Kurashima et al., (1995) Int. Immunol. 7:97
CF5	Landstrom et al., (1997) Int. J. Cancer 71, 451-455
CG5	LeMaoult et al., (2000) J. Immunol. 165:2367
CH5	LeMaoult et al., (1999) J. Immunol. 162:6384-6391
CI5	Leposavic et al., (1995) Neuroimmunodulation 2:100-107
CJ5	Lewin et al., (2002) Blood 100:2235
CK5	Lin et al., (1996) Cancer Res. 56:21
CL5	Lincz et al., (2001) Leuk. and Lymph. 40: 373
CM5	Mackall et al., (1998) Eur. J. Immunol. 28: 1886-1893
CN5	Mackall et al., (1997) Immunol. Rev. 160:91
CO5	Mackall et al., (1997) Immunology Today, 18(5): 245-251
CP5	Mackall et al., (1995) New England J. Med. 332:143
CQ5	Maraskovsky et al., (1997) Cell 89(7): 1011-9
CR5	Martinez et al., (2003) J. Clin Invest. 111:1365
CS5	Masera et al., "Is Orchiectomy Indicated Before BMT in Childhood ALL?" Bone Marrow Transplant, 1991, Vol. 8, No. S1, pp 33-35
CT5	Masuzawa et al., (1994) J. Clin. Invest. 94:1090
CU5	Matera , Neuroimmunomodulation (1997) 4(4): 171-80
CV5	Matzinger et al., (1989) Nature 338:74-60
CW5	Medina et al., (2001) Natl. Immunol. 2:718
CX5	Mercader et al., (2001) PNAS 98(25): 14565-14570
CY5	Miller et al., (1976) J. Immunol. 117:1519
CZ5	Moccagno et al., (1990) Horm. Res. 33(6): 248-55
CA6	Morale et al., (1991) Endocrinology, 128(2): 1073-1085
CB6	Morelli et al., (2001) Semin. Immunol. 13:323-335
CC6	Morrissey et al., (1991) J. Immunol. 146:1547
CD6	Mosley et al., (1998) Cell. Immunol. 189:10
CE6	Murasko et al., (2002) Exp. Gerontol. 37:427-439
CF6	Nabel et al., (1992) Hum. Gene Ther. 3:649-656
CG6	Nicoletti et al., (1993) J. Immunol. 150:543-549
CH6	Nikolic et al., (2000) Blood, 96(3): 1166-1172
CI6	Noach et al., (2002) Blood 100:312
CJ6	Nowak, (1999) New Scientist, pg. 11
CK6	Oberbeck, (2003) J. Surg Res. 113(2): 248-56
CL6	Ohnishi et al., (2003) Int. J. Mol. Med. 1:331
CM6	Oliver et al., (1995) Urol. Int., 54:226-229
CN6	Olsen et al., (2001) Endocrinol. 142:1278
CO6	Olsen, et al., (2001) J. Clin. Invest. 108:697
CP6	Olsen et al., "Androgen Deprivation Induces Phenotypic and Functional Changes in the Thymus of Adult Male Mice," Endocrinology, 1991, pp. 2471-2476, Vol. 129, No. 5
CQ6	Oluwole et al., (1993) Transplantation 56:1523-1527

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	8	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

CR6	Oosterwegel et al., (1997) Immunity 6(3): 351-360
CS6	Orme et al., (1993) J. Infect. Dis. 167:1481
CT6	Ortman et al., (2002) Int. Immunol. 14:813
CU6	Pacheco et al., (1979) J. Parisitol. 65:414
CV6	Panerai et al., (1997) Immunol. Today 4: 191-192
CW6	Panoskaltsis et al., (1999) Frontiers in Bioscience 4:457
CX6	Panoskaltsis-Mortari et al., (2000) Blood 96:4350
CY6	Parkman et al., (1997) Immunol. Rev. 157:73
CZ6	Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269
CA7	Penit et al., (1996) Dev. Immunol. 5:25
CB7	Penit et al., (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5547
CC7	Perriman et al., (1992) Gene 113:157
CD7	Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960
CE7	Plavec et al., (1996) Gene Ther, p. 717-24
CF7	Plosker et al., (1994) Drugs 48:930
CG7	Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676
CH7	Potter et al., (1984) Proc. Natl. Acad. Sci. USA 81:7161-7165
CI7	Prasad et al., (1988) J. Clin. Invest. Oct; 82(4): 1202-1210
CJ7	Randle-Barrett et al., (1995) Dev. Immunol. 4:101
CK7	Ranga et al., (1998) Proc. Natl. Acad. Sci. USA 95:1201
CL7	Rao et al., (1994) Am. J. Reproductive Immunology, 32:238-247
CM7	Renia et al., (1993) J Immunol. 150:1471
CN7	Repique et al., (2002) Infection and Immunity, p. 3318-3323
CO7	Robinson, et al. (2000) Adv. Virus Res. 55:1-74
CP7	Rodrigues et al., (1991) Int. Immunol. 3: 579
CQ7	Romain et al., (1993) Proc. Natl. Acad. Sci. USA 90:5322
CR7	Rosenzweig et al., (1997) Blood, 90(12): 4822-4831
CS7	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.
CT7	Rossi et al., (2002) Blood 100:682-691
CU7	Sato et al., (2004) Br. J. Cancer 90:1334
CV7	Scollay et al., (1980) Eur. J. Immunol. 10:210
CW7	Seder et al., (1994) Annu. Rev. Immunol. 12:635
CX7	Segeren et al., (1999) Br. J. Haem. 105: 127-130
CY7	Sempowski et al., (2002) Mol. Immunol. 38:841-84
CZ7	Sempowski et al., (2000) J. Immunology 164: 2180-2187
CA8	Shaffer et al., (2003) Lancet Oncol. 4:407
CB8	Shippy et al., (1999) Mol. Biotechnol. 12: 117
CC8	Shortman et al., (1990) Seminars in Immuno. 2:3
CD8	Shu et al., (1993) J. Virol. 67:2723
CE8	Shull et al., (1992) Nature 359:693
CF8	Silva et al., (1994) Immunol. 82:244
CG8	Smithson et al., (1995) J. Immunol. 155:3409
CH8	Smithson et al., (1998) J. Immunol. 161:27-35
CI8	Soares et al., J. Immunol. (1998) 161:5909-5917
CJ8	Spitler, "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 1995, Vol. 10, pp. 1-3.
CK8	Starzl et al., (1992) Lancet 339:1579
CL8	Steffens et al., (2000) Clin. Immunol. 97:95
CM8	Stern et al., (1989) Corneal Laser Ablation, 107: 587-592

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
<i>(Use as many sheets as necessary)</i>					
Sheet	9	of	10	Attorney Docket Number 0286336.00159US2/NOR-020US	

CN8	Storek et al., (1997) Am. J. Hematol. 54:131
CO8	Storek et al., (2001) Blood 98:3505
CP8	Strayer et al., (2002) Therapy 5:33-41
CQ8	Suda et al., (1991) J. Immunol. 146:3068
CR8	Suda et al., (1992) J. Immunol. 149(1): 71-76
CS8	Takeoka et al., (1999) Clin. Immunol. 90:388-398
CT8	Talwar, (1999) Immunol. Rev. 171:173-92
CU8	Tang et al., (1997) J. Immunol. 159:117
CV8	Tanghe et al., (2001) Infection and Immunity, p. 3041-3047
CW8	Tanghe et al., (2000) Infection and Immunity 68(7): 3854-3860
CX8	THE JORDAN REPORT 2000: ACCELERATED DEVELOPMENT OF VACCINES, published by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (available at http://www.niaid.nih.gov/publications/pdf/jordan.pdf -last visited Apr. 2004)
CY8	Thurmond et al., (2000) Endocrinol. 141:2309
CZ8	Thomson et al., (1999) Immunology Today 20(1):27
CA9	Thomas-Vaslin et al., (1997) P.N.A.S. (U.S.A.) 94:4598-4603
CB9	Timm et al., (1999) J. Immunol. 162:711
CC9	Tomita et al., (1994) J. Immunol. 153:1087-1098
CD9	Tosi et al., (1982) Clin. Exp. Immunol. Feb; 47(2): 497-504
CE9	Ulmer et al., (1993) Science 259:1745
CF9	Umesaki et al., (1999) Gynecol. Obstet. Invest. 48:66-8
CG9	Utsuyama et al., (1989) Mech. of Ageing Dev. 175-185
CH9	Utsuyama et al., (1995) Mech. Ageing Dev. 107-117
CI9	van Ewijk et al., (1980) J. Histochem. Oct 28(10): 1089
CJ9	van Ewijk et al., (1991) Annu. Rev. Immunol. 9:591-615
CK9	Vickery et al., (1984) LHRH AND ITS ANALOGS: CONTRACEPTIVE & THERAPEUTIC APPLICATIONS (Vickery et al., eds.) MTP Press Ltd, Lancaster, PA
CL9	Viselli et al. (1995) Immunology 84: 337-342
CM9	Viselli et al., (1997) Cellular Immunology 182, 99-104
CN9	Vogelsang et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance," Transplantation Proceedings, 1987, Vol. XIX, No. 1, pp 2658-2661
CO9	Von Freedden-Jeffry et al., (1995) J. Exp. Med. 181:151
CP9	Waldrop et al., (1998) J. Immunol. 161(10): 5284-95
CQ9	Wang et al., (2003) Br. J. Cancer 88:887
CR9	Waterhouse et al., (1998) Proc. Natl. Acad. Sci. USA 95:13959
CS9	Weinberg et al., (1995) Biol. Blood Marrow Transplant1 (1): 18-23
CT9	Weiss et al., (1988) Proc. Natl. Acad. Sci USA 85:573
CU9	Weiss et al., (1992) J. Immunol. 149:2103
CV9	Weksler et al., (2000) Vaccine 18:1624-1628
CW9	Weyand et al., (1998) Mech. Age. Dev. 102: 131-147
CX9	Wiker et al., (1992) Microbiol. Rev. 56: 648
CY9	Wiles et al., (1992) Eur. J. Immunol. 22:1037
CZ9	Wilson et al., (1995) Blood 85:1535
CAA	Windmill et al. (1993) Reprod. Fertil. Devl. 5, 73-81
CBA	Windmill et al., (1998) Tissue Cell 30(1): 104-111
CCA	Woffendin et al., (1994) Proc. Natl. Acad. Sci. USA, 91:11581
CDA	Woffendin et al., (1996) Proc. Natl. Acad. Sci. USA, 93:2889
CEA	Wu et al., (1996) Am. J. Repro. Immunol. 35(6): 510-516

Examiner Signature	Date Considered	
--------------------	-----------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/553594
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	10	of	10	Attorney Docket Number	0286336.00159US2/NOR-020US

CFA	Yang et al., (1994) "The Particle Bombardment System for Mammalian Gene Transfer," In PARTICLE BOMBARDMENT TECHNOLOGY FOR GENE TRANSFER (Yang, N.-S. and Christou, P., eds.), Oxford University Press, New York, pp. 117-141	
CGA	Young et al., (1991) Res. Microbiol. 142:55	
CHA	Zhang et al., (1999) J. Exp. Med. 190:725	
CIA	Zlotnik et al., (1995) Curr. Opin. Immunol. 7:206.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------